SCHEMBL22003804

SCHEMBL22003804

CC(=O)Nc1ccc2c(c1)CN(C(C)C)CC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.49
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP1A2 P05177 1/20 0.46
ADRA2A P08913 1/20 0.46
MAOA P21397 1/20 0.46
SLC6A2 P23975 1/20 0.46
HTR2C P28335 1/20 0.46
SLC6A4 P31645 1/20 0.46
HTR2B P41595 1/20 0.46
BAZ2B Q9UIF8 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2248318 0.82 ACLY (0.53) ACLYGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL15142146 0.81 RAB9A (0.47) NPC1RAB9AKDM4EALDH1A1HSP90AA1
SCHEMBL11741769 0.80 NOTUM (0.58) ACLYGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4591071 0.79 NPC1 (0.53) ACLYGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13180848 0.76 ALDH1A1 (0.52) NPC1RAB9ACYP1A2ADRA2AMAOA
SCHEMBL15142204 0.75 ALDH1A1 (0.51) KDM4EALDH1A1HRH3
SCHEMBL11337517 0.75 BAZ2B (0.51) ACLYNPC1RAB9ACYP1A2ADRA2A
SCHEMBL7817441 0.74 MAPT (0.46) NPC1RAB9AKDM4EALDH1A1HRH3
SCHEMBL29119496 0.74 MLNR (0.51) ACLYNPC1RAB9ACYP1A2ADRA2A
SCHEMBL29119510 0.74 BAZ2B (0.54) NPC1RAB9ABAZ2BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102616-A1 ACLY INHIBITORS AND USES THEREOF Nimbus Artemis, Inc. (US) 2020-05-22 WO disclosed
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG ACLY 1/4885GRIN2D 4252/4885GRIN3B 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.